Back

SLNO Stock

Price Chart

📈
Loading chart for SLNO...
Powered by TradingView

Detailed Market Analysis

Key Levels

Support
$37.52
Resistance
$41.46

Volume & Momentum

Volume
Weak
0.8x avg
Momentum
0%
Weak

Trading Setup

HOLD
Entry $39.49
Stop $37.52
Target $41.46
RSI: 50 | Current: $39.49

Market Sentiment

50
Neutral

Stock Metrics

Daily Vol
0%
VIX Est
20
Weekly
0%

Insider Trading

Insider Role Date Type Value
Manning Meredith Chief Commercial … Mar 27 '26 Sale 228980.0
Huang Michael F. Sr. VP … Mar 27 '26 Sale 200365.0
Abingworth Bioventures VII … Shareholder Aug 11 '25 Proposed Sale 110696581.0
Hirano Patricia C SEE REMARKS Jul 01 '25 Sale 316971.0
PATRICIA HIRANO Officer Jul 01 '25 Proposed Sale 316971.0
Hirano Patricia C SEE REMARKS Jun 24 '25 Option Exercise 11770.0
Hirano Patricia C SEE REMARKS Jun 24 '25 Sale 22410.0
PATRICIA HIRANO Officer Jun 24 '25 Proposed Sale 22410.0

Source: FinViz — Data may be delayed

SLNO News Intelligence (1 articles)

AI-curated news influencing SLNO price, sentiment, and trend

Explore All SLNO News with AI Analysis
Global Markets & Finance
4 hours, 6 minutes ago

Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment

Soleno Therapeutics makes first commercialised drug for extreme hunger caused by Prader-Willi syndrome

Impact on SLNO: The acquisition is likely to have a positive impact on Neurocrine's stock …
Neurocrine is nearing a $2.5bn-plus deal to acquire Soleno Therapeutics, the biotech company behind the … High (80%)
View full analysis →
Financial Times 80% confidence
🤖

AI Analysis

Multi-Provider AI Analysis

Neutral

AI Summary

Loading...

Confidence
0%
AI Model Multi-Provider AI Analysis
Open article